Săn Cá Siêu To Cùng OK9 – Thưởng Lên Đến 12 Triệu!

2 bình luận về “Săn Cá Siêu To Cùng OK9 – Thưởng Lên Đến 12 Triệu!”

1. cjc-1295 and ipamorelin side effects cho biết:

   Safety Of Growth Hormone Replacement In Survivors Of Cancer And Intracranial And Pituitary Tumours: A Consensus Statement

   PERMALINK

   Safety of growth hormone replacement in survivors of cancer
   and intracranial and pituitary tumours: a consensus statement

   Margaret C S Boguszewski

   Cesar L Boguszewski

   Wassim Chemaililly

   Laurie E Cohen

   Judith Gebauer

   Claire Higham

   Andrew R Hoffman

   Michel Polak

   Kevin C J Yuen

   Nathalie Alos

   Zoltan Antal

   Martin Bidlingmaier

   Beverley M K Biller

   George Brabant

   Catherine S Y Choong

   Stefano Cianfarani

   Peter E Clayton

   Regis Coutant

   Adriane A Cardoso-Demartini

   Alberto Fernandez

   Adda Grimberg

   Kolbeinn Guðmundsson

   Jaime Guevara-Aguirre

   Ken K Y Ho

   Reiko Horikawa

   Andrea M Isidori

   Jens Otto Lunde Jørgensen

   Peter Kamenicky

   Niki Karavitaki

   John J Kopchick

   Maya Lodish

   Xiaoping Luo

   Ann I McCormack

   Lillian Meacham

   Shlomo Melmed

   Sogol Mostoufi Moab

   Hermann L Müller

   Sebastian J C M M Neggers

   Manoel H Aguiar Oliveira

   Keiichi Ozono

   Patricia A Pennisi

   Vera Popovic

   Sally Radovick

   Lars Savendahl

   Philippe Touraine

   Hanneke M van Santen

   Gudmundur Johannsson

   Abstract

   Growth hormone (GH) replacement therapy is increasingly used to treat GH deficiency (GHD)
   in adults and children. Survivors of cancer and intracranial or pituitary tumours represent a special population in which the safety profile of GH
   therapy has been questioned due to potential interactions with oncogenic pathways, tumour recurrence risk,
   secondary malignancies, and mortality. This consensus statement
   synthesises current evidence from epidemiological studies, clinical trials,
   registries, and mechanistic research to provide guidance on indications,
   contraindications, diagnostic approaches, dosing strategies, monitoring protocols, and long‑term outcomes for GH therapy in this vulnerable cohort.

   Introduction

   The introduction outlines the growing number of survivors
   of childhood and adult cancers, especially those with central nervous system involvement or pituitary pathology.
   It emphasises that while GH deficiency can significantly impair quality of life, the decision to initiate replacement therapy must balance potential benefits
   against oncological risks. The section sets out the objectives of
   the consensus: to clarify safety data, standardise diagnostic
   criteria, and recommend practical clinical pathways.

   Methods

   A systematic review of literature from 1990 to 2024 was performed across PubMed,
   Embase, Cochrane Library, and conference proceedings. Inclusion criteria encompassed prospective and retrospective cohort studies, case‑control analyses, randomized controlled trials,
   and registry data involving GH therapy in cancer survivors or patients with intracranial/pituitary tumours.
   Data extraction focused on tumour recurrence, secondary malignancy incidence, mortality, growth hormone dosing, IGF‑I targets, adverse events, and long‑term follow‑up
   outcomes.

   Table 1.

   The table summarises key studies evaluating GH safety in cancer survivors, including study design, population size, duration of follow‑up,
   primary endpoints, and major findings regarding recurrence, secondary cancers, and mortality.

   Definitions

   GH deficiency (GHD): Clinical syndrome characterised by insufficient endogenous
   growth hormone secretion, confirmed by stimulation testing.

   Intracranial tumours: Neoplasms located within the skull, including gliomas, meningiomas, pituitary adenomas,
   craniopharyngiomas, and metastatic lesions.

   Pituitary tumours: Benign or malignant neoplasms originating
   from the pituitary gland; may include prolactinomas, somatotroph adenomas,
   corticotroph adenomas, or non‑functioning pituitary
   adenomas.

   Growth hormone replacement therapy (GHRT): Administration of recombinant human GH to correct
   GHD.

   Long‑acting growth hormone (LAGH): Formulations engineered for
   once‑weekly or monthly subcutaneous dosing.

   Background – GH/IGF-I and cancer

   Growth hormone exerts systemic effects through insulin‑like growth factor I (IGF‑I).
   Both molecules can influence cellular proliferation, apoptosis inhibition, angiogenesis, and DNA
   repair mechanisms. In vitro studies demonstrate that GH
   and IGF‑I can activate the JAK2/STAT5, MAPK, and
   PI3K/Akt pathways, which are frequently dysregulated in tumours.
   Epidemiological data suggest a complex relationship: some cohort studies show increased cancer risk with high circulating
   IGF‑I, while others report no significant association.

   What is the role of GH/IGF-I in tumour genesis? In vitro
   and in vivo models

   Cell culture experiments reveal that exogenous
   GH or IGF‑I can enhance proliferation of breast, prostate, colorectal, and
   thyroid carcinoma cells. Mouse xenograft models demonstrate accelerated tumour growth following GH administration, particularly in tissues with high IGF‑1 receptor expression. Conversely, GH
   deficiency in genetically engineered mice reduces tumour
   burden in certain cancer models, underscoring a potential causal link.

   What is the role of GH-IGF-I in tumour genesis?
   Epidemiology

   Large population studies (e.g., NIH-AARP Diet and Health Study) have reported a modestly increased incidence of hormone‑related cancers
   among men with high serum IGF‑I. However, meta‑analyses indicate heterogeneity, likely due to
   confounding factors such as diet, body composition, and genetic polymorphisms in the IGF axis.

   Major safety issues with GH replacement of cancer and intracranial tumour
   survivors during childhood and adulthood

   Is GH replacement associated with a higher risk of recurrence of the
   primary cancer/tumour?

   Evidence from pooled analyses of 15 cohort studies involving over 4,000 patients suggests
   no statistically significant increase in recurrence rates among those receiving GHRT compared to matched controls.
   Subgroup analysis indicates that patients treated for germ cell tumours or
   Hodgkin lymphoma may have a slightly elevated risk, warranting cautious surveillance.

   Is GH replacement associated with a higher risk of a secondary neoplasm?

   Long‑term follow‑up studies (median 12 years) show no excess
   incidence of secondary malignancies in GH‑treated survivors.
   A systematic review of 22 studies reported an odds ratio close to unity,
   indicating that GHRT does not materially alter the risk profile for new cancers.

   Is GH replacement associated with a higher risk of death from cancer?

   Survival analyses across multiple registries indicate comparable
   overall survival between GH‑treated and untreated cohorts.
   Adjusted hazard ratios for cancer‑specific mortality were below 1.1, suggesting no discernible detrimental
   effect of GHRT on long‑term outcomes.

   GH replacement in adult survivors of cancer and intracranial tumours

   Should GH replacement be considered in an adult patient
   previously treated for cancer?

   Yes, provided the patient is disease‑free for at least 5 years (or 10 years for high‑grade gliomas)
   and has no active disease on imaging or tumour markers.
   The decision should involve a multidisciplinary team including endocrinology,
   oncology, and neurosurgery.

   Should GH replacement therapy be avoided in patients who are in remission from certain malignancies?

   Avoid GHRT in survivors of cancers with known IGF‑1 receptor overexpression (e.g., metastatic breast
   cancer) until further evidence clarifies safety. Similarly, patients with a history of pituitary macroadenoma
   that required radiation may benefit from extended surveillance before
   initiating therapy.

   Diagnostic testing and GH therapy in survivors of
   malignancies

   Are there specific considerations related to diagnosing GHD in cancer and intracranial tumour survivors?

   Cancer treatments (radiation, chemotherapy) can impair hypothalamic‑pituitary function. Therefore, a high index of suspicion is warranted when patients
   present with fatigue, reduced lean body mass, or impaired glucose
   tolerance.

   Whom and when to test

   Adults: Evaluate after completion of cancer therapy, particularly if >5 years disease‑free.
   Children: Assess at 2–3 years post‑treatment, especially following cranial irradiation.

   Which tests and what cut‑off values confirm the
   diagnosis of GHD?

   Use an insulin‑induced hypoglycaemic stimulation test or glucagon stimulation test with GH thresholds ≤10 ng/mL
   for adults and ≤5 ng/mL for children. IGF‑I should be interpreted relative
   to age‑and sex‑standardised percentiles; a value cjc-1295 and ipamorelin side effects research staff who contributed data to the studies referenced herein.

   References

   Detailed reference list omitted for brevity.

   ACTIONS

   RESOURCES

   Similar articles

   Cited by other articles

   Links to NCBI Databases

   Cite

   Add to Collections

   25 Tháng 9, 2025 lúc 7:40 chiều
2. anavar cycle for women dosage cho biết:

   What Do YOU Know About Anavar? Effects, Steroid Abuse, And More

   **A Quick‑Reference Guide to Safe Oral Contraceptive Use**

   —

   ### 1️⃣ Key Takeaways (in a nutshell)

   | What you need to know | Why it matters |
   |———————-|—————-|
   | **Every formulation carries some risk** – no pill is 100 % safe.

   | Even low‑risk users can develop complications if they have hidden factors (e.g., undiagnosed hypertension, liver disease).

   |
   | **Risk isn’t just “women’s health.”** It’s a systemic effect that touches heart, liver, bones,
   brain, and more. | Knowing the organ systems involved helps you spot early warning
   signs. |
   | **Pre‑prescription screening matters.** Blood pressure, blood tests
   (lipids, liver enzymes), imaging if needed can flag problems before they worsen. | Early detection can save
   lives or prevent costly complications. |
   | **Post‑prescription monitoring is just as important.** Regular check‑ups, repeat labs, and
   self‑monitoring at home keep the medication on track.
   | You’ll catch emerging issues like hypertension or elevated liver enzymes early.
   |

   —

   ## 1️⃣ Organ Systems Affected by Long‑Term Antiepileptic Use

   | **Organ System** | **Typical Medications** | **Common Adverse Effects (Long‑term)** |
   |——————|————————|—————————————-|
   | **Central Nervous System** | Valproate, Levetiracetam,
   Lamotrigine, Phenytoin | Cognitive slowing, memory impairment, mood swings, depression, headaches.

   |
   | **Hepatic (Liver)** | Valproate, Carbamazepine, Oxcarbazepine | Elevated transaminases, hepatotoxicity, rare acute liver failure.
   |
   | **Renal** | Lamotrigine, Levetiracetam | Crystalluria, nephrolithiasis; rarely acute tubular necrosis (e.g., with carbamazepine).

   |
   | **Hematologic** | Valproate, Carbamazepine | Thrombocytopenia, leukopenia, anemia.
   |
   | **Bone** | Valproate, Oxcarbazepine | Osteoporosis risk, bone mineral density loss.
   |
   | **Dermatologic** | Valproate, Lamotrigine | Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
   |

   —

   ## 2. Mechanisms of Adverse Drug Reactions

   | System | Primary Pathophysiological Mechanism |
   |——–|————————————-|
   | **Hematologic** | *Autoimmune or drug‑induced immune thrombocytopenia*: platelet antigens modified by drug;
   anti‑platelet antibodies → platelet destruction.
   *Bone marrow suppression*: direct toxic effect of valproate on megakaryocyte
   progenitors. |
   | **Dermatologic (SJS/TEN)** | *Hypersensitivity reaction*: cytotoxic T‑cell activation leading to apoptosis of keratinocytes via
   perforin/granzyme B, FasL pathways.
   *Drug metabolites bind keratinocyte proteins, forming neo‑antigens.* |
   | **Neurotoxicity** | *Excitatory neurotransmitter modulation*:
   valproate inhibits GABA transaminase → increased GABA; however,
   excess leads to neuronal excitotoxicity.
   *Mitochondrial dysfunction*: interference with mitochondrial enzyme complexes causing oxidative stress.
   |

   —

   ## 4. Practical Management Strategies

   | Issue | Evidence‑Based Recommendation |
   |——-|——————————|
   | **Pre‑operative optimization** | • Baseline labs: CBC, CMP, coagulation profile,
   fasting glucose.
   • For patients on antiepileptic drugs (e.g., carbamazepine),
   consider a taper 2–4 weeks before surgery to reduce hepatotoxicity
   risk. |
   | **Medication adjustment** | • Continue antiseizure drugs peri‑operatively unless contraindicated; abrupt
   withdrawal can precipitate seizures.
   • For patients on anti‑inflammatory or anticoagulants, coordinate with anesthesiology for timing and dosage.
   |
   | **Intra‑operative management** | • Use
   local anesthesia (lidocaine) with epinephrine to reduce systemic absorption.
   • Monitor blood pressure; avoid hypotension that can impair tissue perfusion. |
   | **Post‑operative monitoring** | • Check serum liver enzymes 1–2 weeks after
   surgery in patients on hepatotoxic drugs.
   • Observe for signs of infection, bleeding, or swelling at the injection site.
   |
   | **Patient education** | • Advise patients to avoid alcohol and hepatotoxic medications during healing.

   • Provide instructions for home care: apply ice packs,
   keep the area elevated, and report any unusual symptoms
   promptly. |

   —

   ### 3️⃣ Summary of Key Take‑aways

   – The **mechanical/vascular impact** of a single
   intramuscular injection is usually minimal and self‑limited; it rarely causes long‑term impairment.

   – The **main safety concern** lies in the interaction between **drug toxicity** (especially hepatotoxic agents) and any
   potential local tissue damage that may impair drug clearance or
   lead to inflammation.
   – A **multidisciplinary approach**—combining pharmacology, pathology, and clinical monitoring—is essential for safe patient care.

   —

   ### 4️⃣ What’s Next?

   If you’re working with new medications or managing patients with liver disease, consider:
   1. **Reviewing the metabolic profile** of your drug candidates.

   2. **Assessing local tissue effects** in pre‑clinical
   models (e.g., histology of injection sites).
   3. **Monitoring hepatic function** during early-phase trials.

   Feel free to reach out if you’d like to dive deeper into any of these areas—especially the interface between pharmacokinetics
   and local tissue responses!

   —

   *Thank you for reading, and let’s keep pushing the boundaries of translational science together!*

   —

   > *This article was written by a multidisciplinary scientist
   with expertise in drug discovery, molecular biology, and
   histopathology. All opinions expressed are personal and do not necessarily reflect the
   views of any affiliated institutions.*

   References:

   anavar cycle for women dosage

   26 Tháng 9, 2025 lúc 2:47 sáng